biotech (il settore del momento) (1 Viewer)

[osinod]

sono sempre stato un nick geniale ma nello stesso dal carattere difficile

pero' sono sempre stato obbiettivo e continuo a esserlo

ho lasciato altri forum perche' non mi piaceva assolutamente come venivano gestiti


detto questo pero' debbo dire che a livello di spunti e di news riportate sono distanti anni luce da questa sezione esteri di IO

è autocritica certo ma è la realta'

in altre sezioni ad esempio quella obbligazioni grazie anche al lavoro di 98 mark hanno raggiunto un bel livello


ad esempio questa news lo presa da altri forum e fino a che non ci sara' lo


stesso livello di abbondanza di segnalazioni e news qui saremo all' anno zero


ecco la "news" rubata:



se' guardate nell' ultimo mese lo short su' sqnm è sceso quasi di 8 milioni circa la meta'

be' è un segnale importantissimo :

% Held by Insiders[SIZE=-1]1[/SIZE]:21.57%%

Held by Institutions[SIZE=-1]1[/SIZE]:80.70%

Shares Short (as of 12-May-09)[SIZE=-1]3[/SIZE]:8.10M

Short Ratio (as of 12-May-09)[SIZE=-1]3[/SIZE]:0.5

Short % of Float (as of 12-May-09)[SIZE=-1]3[/SIZE]:13.40%

Shares Short (prior month)[SIZE=-1]3[/SIZE]:15.54M

 

[osinod]

bando alle ciance le migliori sono :


cege

ljpc

altu

 

[osinod]

a me non sembra male neppure ulu stavo guardando il mercato otc scgy ha fatto un modesto 900% in tre giorni....

non l' avevo ancora vista molto molto bella ulu

complimenti per la segnalazione


4 occhi vedono meglio di due

 

[HPLovecraft]

Che ne' dici di NEXM? per me è pronta x andare a chiudere un bel gap..

 

[learcario]

Tratto da http://shortsqueeze.com/, in data 8 giugno 2009

Sequenom Inc. $ 3.53
SQNM -0.07
Short Interest (Shares Short) 8,102,500
Days To Cover (Short Interest Ratio) 0.8
Short Percent of Float 16.06 %
Short Interest - Prior 15,544,500
Short % Increase / Decrease -47.88 %
Short Squeeze Ranking™ -8

% From 52-Wk High ($ 29.14 ) -725.50 %
% From 52-Wk Low ($ 2.86 ) 18.98 %
% From 200-Day MA ($ 14.78 ) -318.70 %
% From 50-Day MA ($ 6.84 ) -93.77 %
Price % Change (52-Week) -61.40 %

Shares Float 50,460,000
Total Shares Outstanding 61,134,052
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 215,803,204
Trading Volume - Today 2,610,361 (5 giugno 2009)
Trading Volume - Average 10,490,800
Trading Volume - Today vs. Average 24.88 %
Earnings Per Share -0.94
PE Ratio
Record Date 2009-MayB
Sector Healthcare
Industry Biotechnology
Exchange NAS

 

[mistikk]

time out

 

[learcario]

Osinod, cosa ne pensi di PGNX ?

tratto da http://shortsqueeze.com

Progenics Pharmaceuticals Inc. $ 5.04
PGNX -0.01
Short Interest (Shares Short) 1,862,000
Days To Cover (Short Interest Ratio) 9.7
Short Percent of Float 7.03 %
Short Interest - Prior 1,953,300
Short % Increase / Decrease -4.67 %
Short Squeeze Ranking™ -49 %
From 52-Wk High ($ 17.94 ) -255.95 %
% From 52-Wk Low ($ 4.97 ) 1.39 %
% From 200-Day MA ($ 7.00 ) -38.89 %
% From 50-Day MA ($ 5.33 ) -5.75 %
Price % Change (52-Week) -71.40 %
Shares Float 26,480,000
Total Shares Outstanding 31,022,934
% Owned by Insiders 5.54 %
% Owned by Institutions 87.60 %
Market Cap. $ 156,355,587
Trading Volume - Today 148,627
Trading Volume - Average 192,300 Trading Volume - Today vs. Average 77.29 %
Earnings Per Share -1.04 PE Ratio


Altri dati chiave.

http://finance.yahoo.com/q/ks?s=PGNX


Tratto da http://community.smallcapnetwork.com

Progenics Pharmaceuticals (PGNX) http://www.progenics.com/ trading on the Nasdaq in $5 range with a market cap of $155M seems to be the darling of the messages boards today. Its average three month trading volume is 180,194 shares and it has soared past that number today.
Last week, PGNX announced the discontinuation of development for PRO 206, a pre-clinical compound for the treatment of hepatitis C virus (HCV) infection. The decision was made as part of a portfolio review, and is in line with the Company's ongoing initiative to allocate resources to the most important programs in order to increase its operating efficiencies.
Last month PGNX posted some disappointing Q1 numbers. PGNX had a net loss of $1.8 million or $0.06, basic and diluted, per share, compared to $15.5 million or $0.52, basic and diluted, per share in the first quarter of 2008. Progenics ended the quarter with cash, cash equivalents and marketable securities of $127.7 million, compared to $141.4 million at December 31, 2008. Cash on hand is always a healthy indicator per-empting loans.
Revenues for the quarter totaled $20.9 million, compared to $14.8 million for the same period of 2008, primarily reflecting full recognition in the first quarter of 2009 of a $15.0 million upfront payment received in the fourth quarter of 2008 from Ono Pharmaceutical Co., Ltd. (Tokyo: OSE-TYO: 4528), Progenics' Japanese collaborator.
PGNX has an ongoing deal with giant Wyeth (WYE) even the pharma behemoth will likely decrease its reimbursements to Progenics this year. Also in PGNX's corner is a recent belt tightening: 10 percent staff reduction, eliminated salaries for Sr. Mgmt, reduced bonuses and a cut back on consultants.
PGNX also has some very positive numbers; net sales were up 23 percent from the prior quarter and global net sales of RELISTOR (the Company's primary product) for the first quarter of 2009 were $1.9 million, a growth of 23 percent compared to $1.5 million in the fourth quarter of 2008. This quarterly increase includes a 42% increase in U.S. RELISTOR sales from $0.8 million in the fourth quarter of 2008 to $1.2 million in the first quarter of 2009. Also the number of U.S. institutions ordering RELISTOR in the first quarter of 2009 grew by approximately 27% over the fourth quarter of 2008 as formulary approvals continue to increase.
At $5, PGNX is far off its 52-week high of $17.94 on 06-17-08 and is below both its 50-day and 200-day moving average. Its trailing twelve month revenues are $73.81M. PGNX's shares out versus float ratio is near-parity.